Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-09 3:43 pm Purchase |
2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
The Vanguard Group | 5,107,991 7.830% |
2,173,567 (+74.07%) |
Filing History |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BLACKROCK INC BLK |
4,962,362 7.600% |
1,157,183 (+30.41%) |
Filing History |
| 2022-02-01 12:25 pm Sale |
2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
Victory Capital Management, Inc. | 8,828 0.010% |
-2,719,209 (-99.68%) |
Filing History |
| 2022-01-03 4:34 pm Purchase |
2021-12-21 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 5,803,700 8.900% |
2,884,229 (+98.79%) |
Filing History |
| 2021-12-08 2:06 pm Purchase |
2021-11-29 | 13G | CytomX Therapeutics, Inc. CTMX |
RTW Investments, LP | 5,868,326 8.990% |
5,868,326 (New Position) |
Filing History |
| 2021-05-03 5:19 pm Sale |
2021-04-29 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 2,919,471 4.500% |
-2,657,000 (-47.65%) |
Filing History |
| 2021-02-16 3:57 pm Sale |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
PERCEPTIVE ADVISORS LLC | 2,577,043 4.300% |
-676,880 (-20.80%) |
Filing History |
| 2021-02-11 5:27 pm Purchase |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 5,576,471 12.100% |
950,060 (+20.54%) |
Filing History |
| 2021-02-10 10:46 am Purchase |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
The Vanguard Group | 2,934,424 6.350% |
244,820 (+9.10%) |
Filing History |
| 2021-02-02 3:13 pm Sale |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
Victory Capital Management, Inc. | 2,728,037 7.110% |
-85,414 (-3.04%) |
Filing History |
| 2021-01-29 4:30 pm Purchase |
2021-01-29 | 13G | CytomX Therapeutics, Inc. CTMX |
RA Capital Management, L.P. | 3,500,000 5.800% |
3,500,000 (New Position) |
Filing History |
| 2021-01-29 09:56 am Sale |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BLACKROCK INC BLK |
3,805,179 8.200% |
-210,869 (-5.25%) |
Filing History |
| 2021-01-26 5:20 pm Purchase |
2021-01-25 | 13G | CytomX Therapeutics, Inc. CTMX |
Point72 Asset Management, L.P. | 5,523,906 9.100% |
5,523,906 (New Position) |
Filing History |
| 2020-11-10 4:58 pm Purchase |
2020-11-06 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 4,626,411 10.000% |
1,437,463 (+45.08%) |
Filing History |